Claims
- 1. A polymer with a hydrolytically labile polymer backbone, said polymer having the structure: ##STR17## wherein R.sub.9 is an alkyl, aryl or alkylaryl group with up to 18 carbon atoms having a pendent carboxylic acid group on the benzyl ester thereof;
- R.sub.12 is an alkyl, aryl or alkylaryl group with up to 18 carbon atoms having a pendent carboxylic acid ester group selected from the group consisting of straight and branched alkyl and alkylaryl esters containing up to 18 carbon atoms and ester derivatives of biologically and pharmaceutically active compounds covalently bonded to said polymer, provided that said ester group is not a benzyl group or a group that is removed by hydrogenolysis;
- each R.sub.7 is independently an alkylene group containing up to four carbon atoms;
- A is selected from the group consisting of: ##STR18## wherein R.sub.8 is selected from the group consisting of saturated and unsaturated, substituted and unsubstituted alkyl, aryl and alkylaryl groups containing up to 18 carbon atoms;
- k is between about 5 and about 3,000; and
- x and f independently range from zero to less than one.
- 2. The polymer of claim 1, wherein x and f are both zero.
- 3. The polymer of claim 1, wherein R.sub.9 has a structure selected from the group consisting of: ##STR19## wherein R.sub.2 is hydrogen or a benzyl group and a and b are independently zero, one or two.
- 4. The polymer of claim 3, wherein x is greater than zero and R.sub.12 has a structure selected from the group consisting of: ##STR20## wherein R.sub.1 is selected from the group consisting of straight and branched alkyl and alkylaryl groups containing up to 18 carbon atoms and derivatives of biologically and pharmaceutically active compounds covalently bonded to said polycarbonate, provided that R.sup.1 is not a benzyl group or a group that is removed by hydrogenolysis; and c and d are independently zero, one or two.
- 5. The polymer of claim 4, wherein R.sub.9 has the structure: ##STR21## and R.sub.12 has the structure: ##STR22## wherein a and c are two and b and d are one.
- 6. The polymer of claim 1, wherein x is between about 0.5 and about 0.75.
- 7. The polymer of claim 1, wherein said ester group of said pendent carboxylic acid ester group of R.sub.12 is a straight-chained alkyl group selected from the group consisting of ethyl, butyl, hexyl and octyl groups.
- 8. The polymer of claim 1, wherein said pendent group of R.sub.9 is a benzyl carboxylate group.
- 9. The polymer of claim 1, wherein f is greater than zero.
- 10. The polymer of claim 9, wherein each R.sub.7 group is ethylene.
- 11. The polymer of claim 9, wherein k is between about 20 and about 200.
- 12. The polymer of claim 9, wherein f ranges between about 0.05 and about 0.95.
- 13. An implantable medical device in the form of a sheet consisting essentially of the polymer of claim 9 for use as a barrier for surgical adhesion prevention.
- 14. A method for preventing the formation of adhesions between injured tissues comprising inserting as a barrier between said injured tissues a sheet consisting essentially of the polymer of claim 9.
- 15. An implantable medical device comprising the polymer of claim 1.
- 16. The implantable medical device of claim 15, wherein the surface of said device is coated with said polymer.
- 17. The implantable medical device of claim 15, comprising a biologically or pharmaceutically active compound in combination with said polymer, wherein said active compound is present in amounts sufficient for therapeutically effective site-specific or systemic drug delivery.
- 18. The implantable medical device of claim 17, wherein said biologically or pharmaceutically active compound is covalently bonded to said polymer.
- 19. A method for site-specific or systemic drug delivery comprising implanting in the body of a patient in need thereof an implantable drug delivery device comprising a therapeutically effective amount of a biologically or pharmaceutically active compound in combination with the polymer of claim 1.
- 20. The method of claim 19, wherein said biologically or pharmaceutically active compound is covalently bonded to said polymer.
- 21. A controlled drug delivery system comprising a biologically or pharmaceutically active agent physically coated with the polymer of claim 1.
- 22. A controlled drug delivery system comprising the polymer of claim 1 physically admixed with a biologically or pharmaceutically active agent.
- 23. A controlled drug delivery system comprising a biologically or pharmaceutically active agent physically embedded or dispersed into a polymeric matrix formed from the polymer of claim 1.
- 24. A method of regulating cellular attachment, migration and proliferation on a polymeric substrate, comprising contacting living cells, tissues or biological fluids containing living cells with the polymer of claim 1.
- 25. The method of claim 24, wherein said polymer is in the form of a coating on a medical implant.
- 26. The method of claim 24, wherein said polymer is in the form of a film.
- 27. The method of claim 24, wherein said polymer is in the form of a polymeric tissue scaffold.
- 28. The polymer of claim 1, comprising a polycarbonate in which A is: ##STR23##
- 29. The polymer of claim 1, comprising a polyarylate in which A is: wherein R.sub.8 is selected from the group consisting of saturated and unsaturated, substituted and unsubstituted alkyl groups containing from 2 to 12 carbon atoms.
- 30. The polyarylate of claim 29, wherein R.sub.8 is selected from the group consisting of --CH.sub.2 --C(.dbd.O)--, --CH.sub.2 --CH.sub.2 --C(.dbd.O)--, --CH.dbd.CH-- and (--CH.sub.2 --).sub.z, wherein z is an integer between 2 and 8, inclusive.
- 31. The polyarylate of claim 29, wherein R.sub.8 is selected from the group consisting of substituted and unsubstituted aryl and alkylaryl groups containing from 6 to 12 carbon atoms.
- 32. The polyarylate of claim 31, wherein R.sub.8 is a phenyl group.
- 33. A method for the selective removal of pendent ester side chains comprising the steps of:
- preparing a reaction mixture of the polymer of claim 1, in which the pendent group of R.sub.9 is a benzyl carboxylate group, in an anhydrous reaction solvent consisting essentially of one or more solvents selected from the group consisting of N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) and N-methylpyrrolidone (NMP); and
- contacting said reaction mixture with a palladium catalyst in the presence of a hydrogen source, so that the benzyl groups of said pendent benzyl carboxylate groups are selectively removed by hydrogenolysis.
- 34. The method of claim 33, wherein said hydrogen source comprises hydrogen gas.
- 35. The method of claim 34, wherein said hydrogen source further comprises 1,4-cyclohexadiene added to said reaction mixture.
- 36. The method of claim 34, wherein said ester group of said pendent carboxylic acid ester group of R.sub.12 is a straight-chained alkyl group selected from the group consisting of ethyl, butyl, hexyl and octyl groups.
- 37. The method of claim 33, wherein said hydrogen source comprises 1,4-cyclohexadiene added to said reaction mixture.
- 38. The method of claim 37, wherein said 1,4-cyclohexadiene is added to said reaction mixture before said reaction mixture is contacted with said palladium catalyst.
- 39. The method of claim 33, wherein said palladium catalyst comprises palladium on barium sulfate.
- 40. The method of claim 33, wherein A is: ##STR24## so that said polymer is a polycarbonate.
- 41. The method of claim 40, wherein f is greater than zero.
- 42. The method of claim 33, wherein A is: ##STR25## so that said polymer is a polyarylate.
- 43. The method of claim 42, wherein f is greater than zero.
- 44. The method of claim 33, wherein x is zero.
- 45. The method of claim 33, wherein R.sub.9 has a structure selected from the group consisting of ##STR26## wherein R.sub.2 is a benzyl group and a and b are independently zero, one or two.
- 46. The method of claim 45, wherein R.sub.9 has the structure: ##STR27## wherein a is two and b is one.
- 47. The method of claim 45, wherein R.sub.12 has a structure selected from the group consisting of: ##STR28## wherein R.sub.1 is selected from the group consisting of straight and branched alkyl and alkylaryl groups containing up to 18 carbon atoms and derivatives of biologically and pharmaceutically active compounds covalently bonded to said polymer, with the proviso that R.sub.1 is not a benzyl group or a group that is removed by hydrogenolysis, and c and d are independently zero, one or two.
- 48. The method of claim 46, wherein R.sub.12 has the structure: ##STR29## wherein c is two and d is one.
- 49. The method of claim 48, wherein a and c are two and b and d are one.
- 50. The method of claim 33, wherein x is between about 0.50 and 0.75.
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Provisional patent application Ser. No. 60/064,656 filed on Nov. 7, 1997 by Joachim B. Kohn, Durgadas Bolikal, George L. Brode, Sylvie I. Ertel, Shuiyun Guan and John Kemnitzer entitled, "Biodegradable Anionic Polymers Derived from the Amino Acid L-Tyrosine," now U.S. Pat. No. 5,293,682 the disclosure of which is incorporated herein by reference.
GOVERNMENT LICENSE RIGHTS
The U.S. government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as required by the terms of Grant Nos. GM-39455 and GM-49849 awarded by the National Institutes of Health.
US Referenced Citations (7)